BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy

Hamy, Anne-Sophie; Bièche, Ivan; Lehmann-Che, Jacqueline; Scott, Véronique; Bertheau, P; Jm, Guinebretière; Matthieu, M.-C.; Sigal‐Zafrani, Brigitte; Tembo, O.; Marty, M.; Asselain, Bernard; Spyratos, Frédérique; Crémoux, Patricia de

doi:10.1007/s10549-016-3961-2

Cited by 44 publications

(39 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this is the first report to describe the upregulation of survivin by eribulin, while other microtubule inhibitors, paclitaxel and vincristine, were shown to enhance the expression of survivin [12]. Survivin is highly expressed in malignant tissues but it is not expressed in normal tissues [25], and the upregulation of survivin has been reported to have clinical importance as a poor prognostic marker in breast cancer [26][27][28]. We found a novel HDAC inhibitor OBP-801 to be a promising candidate for enhancing the effect of eribulin by suppressing survivin in TNBC (Fig.…”

Section: Discussionmentioning

confidence: 78%

The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway

Ono

Sowa

Horinaka

et al. 2018

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Eribulin was approved for the treatment of metastatic breast cancer through the EMBRACE trial, and a subgroup analysis in this clinical trial indicated the efficacy of eribulin in patients with TNBC. However, the prognosis of patients with TNBC is still poor due to various molecular characteristics. Therefore, there is an urgent need for a more effective treatment for the management of TNBC. Methods We investigated the synergistic effect of a novel histone deacetylase (HDAC) inhibitor, OBP-801, and eribulin in TNBC cell lines because OBP-801 has been known to enhance the anti-tumor activities of other chemotherapeutic agents. The cell growth was analyzed, and the flow cytometry analysis was conducted to evaluate the effects on cell cycle and the induction of apoptosis. The mechanism underlying the enhancement of inhibition of TNBC cell growth was investigated through Western blot analyses. Results The combination treatment of OBP-801 with eribulin showed the synergistic inhibition of the growth in TNBC cells, involved with the enhancement of apoptosis. We, for the first time, found that eribulin upregulated survivin and also that OBP-801 could remarkably suppress the upregulation of survivin by eribulin. Moreover, this combination potently suppressed Bcl-xL and the MAPK pathway compared with either agent alone. Conclusion We found that the combination of OBP-801 and eribulin synergistically inhibited the growth with apoptosis in TNBC cells, suggesting that this combination might be a promising novel strategy for treating TNBC patients.

show abstract

Section: Discussionmentioning

confidence: 78%

The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway

Ono

Sowa

Horinaka

et al. 2018

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Survivin is often overexpressed in breast cancer [29], and is associated with less apoptosis [30], poor overall survival [31], and resistance to neoadjuvant chemotherapy [32]. Several therapeutic approaches targeting survivin have been tested, including inhibition of survivin transcription, post-translational inhibition of survivin, vaccines against survivin, and gene therapy approaches such as gene editing [33].…”

Section: Discussionmentioning

confidence: 99%

Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells

et al. 2017

View full text Add to dashboard Cite

In this study, we investigated anti-tumor activity and associated molecular mechanism of action of Salicylate ●Phenanthroline Copper (II) Complex in triple-negative breast cancer. Salicylate ●Phenanthroline Copper (II) Complex inhibited the growth of four breast cancer cell lines (MCF-7, T47D, MDA-MB-231 and BT-20) and induced apoptosis in a concentration-dependent manner. The effect was more profound in MDA-MB-231 and BT-20 triple-negative breast cancer cell lines. Western blot showed that the expression of the apoptosis-related protein Bcl-2, Bcl-xl and survivin was significantly reduced in MDA-MB-231 after treatment with Salicylate ●Phenanthroline Copper (II) Complex. In vivo, Salicylate ●Phenanthroline Copper (II) Complex administration significantly attenuated tumor growth of MDA-MB-231 xenografts, and the expression levels of Bcl-2, Bcl-xL and survivin were reduced as measured by immunohistochemical staining. These data suggest that Salicylate ●Phenanthroline Copper (II) Complex is a promising novel therapeutic drug for triple-negative breast cancer and warrants further study.

show abstract

“…The primary objective of the trial was pathological complete response (pCR) evaluated according to Chevallier criteria (15). Secondary objectives were to define genomic profiles of success (pCR) or failure of each type of treatment and were published elsewhere together with quality control criteria (16)(17)(18).…”

Section: Methodsmentioning

confidence: 99%

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients

Crémoux

Hamy

Lehmann-Che

et al. 2018

View full text Add to dashboard Cite

show abstract

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy

Cited by 44 publications

References 50 publications

The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway

The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway

Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients

Contact Info

Product

Resources

About